Identification and quantification of peptides and proteins secreted from prostate epithelial cells by unbiased liquid chromatography tandem mass spectrometry using goodness of fit and analysis of variance

Journal of Proteomics

Volumn 75, Issue 4, 2012, Pages 1303-1317

  Florentinus, Angelica K ^a   Bowden, Peter ^a   Sardana, Girish ^a   Diamandis, Eleftherios P ^a   Marshall, John G ^a  

^a RYERSON UNIVERSITY   (Canada)

Author keywords

Chromatography optimization; Epithelial cell line; LC ESI MS MS; Prostate cancer; Relative quantification of measured ion intensity; Secreted proteins

Indexed keywords

PEPTIDE; PROTEIN; TRYPSIN;

AMINO ACID SEQUENCE; ANALYSIS OF VARIANCE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CHI SQUARE TEST; CONTROLLED STUDY; FALSE POSITIVE RESULT; HUMAN; HUMAN CELL; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; NOISE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; TANDEM MASS SPECTROMETRY;

14-3-3 PROTEINS; ALGORITHMS; ANALYSIS OF VARIANCE; CHROMATOGRAPHY, LIQUID; EPITHELIAL CELLS; FALSE POSITIVE REACTIONS; HUMANS; IONS; MALE; MODELS, STATISTICAL; PEPTIDES; PROSTATE; REPRODUCIBILITY OF RESULTS; SOFTWARE; TANDEM MASS SPECTROMETRY;

EID: 84855891214     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.11.002     Document Type: Article

References (80)

1. Griffin N.M., Yu J., Long F., Oh P., Shore S., Li Y., et al. Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol 2011, 28:83-89.
2. Simpson K.L., Whetton A.D., Dive C. Quantitative mass spectrometry-based techniques for clinical use: biomarker identification and quantification. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1240-1249.
3. Schenk S., Schoenhals G.J., de Souza G., Mann M. A high confidence, manually validated human blood plasma protein reference set. BMC Med Genomics 2008, 1:41.
4. Mueller L.N., Brusniak M.Y., Mani D.R., Aebersold R. An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. J Proteome Res 2008, 7:51-61.
5. States D.J., Omenn G.S., Blackwell T.W., Fermin D., Eng J., Speicher D.W., et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 2006, 24:333-338.
6. Mortensen P., Gouw J.W., Olsen J.V., Ong S.E., Rigbolt K.T., Bunkenborg J., et al. MSQuant, an open source platform for mass spectrometry-based quantitative proteomics. J Proteome Res 2010, 9:393-403.
7. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002, 74:5383-5392.
8. Craig R., Beavis R.C. A method for reducing the time required to match protein sequences with tandem mass spectra. Rapid Commun Mass Spectrom 2003, 17:2310-2316.
9. Craig R., Beavis R.C. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004, 20:1466-1467.
10. Bowden P., Beavis R., Marshall J. Tandem mass spectrometry of human tryptic blood peptides calculated by a statistical algorithm and captured by a relational database with exploration by a general statistical analysis system. J Proteomics 2009, 73:103-111.
11. Zhu P., Bowden P., Tucholska M., Marshall J.G. Chi-square comparison of tryptic peptide-to-protein distributions of tandem mass spectrometry from blood with those of random expectation. Anal Biochem 2011, 409:189-194.
12. Zhu P., Bowden P., Tucholska M., Zhang D., Marshall J.G. Peptide-to-protein distribution versus a competition for significance to estimate error rate in blood protein identification. Anal Biochem 2011, 411:241-253.
13. Zybailov B., Mosley A.L., Sardiu M.E., Coleman M.K., Florens L., Washburn M.P. Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae. J Proteome Res 2006, 5:2339-2347.
14. Griffin T.J., Gygi S.P., Rist B., Aebersold R., Loboda A., Jilkine A., et al. Quantitative proteomic analysis using a MALDI quadrupole time-of-flight mass spectrometer. Anal Chem 2001, 73:978-986.
15. Dicker L., Lin X., Ivanov A.R. Increased power for the analysis of label-free LC-MS/MS proteomics data by combining spectral counts and peptide peak attributes. Mol Cell Proteomics 2011, 9:2704-2718.
16. Freue G.V., Sasaki M., Meredith A., Gunther O.P., Bergman A., Takhar M., et al. Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics 2010, 9:1954-1967.
17. Ardekani A.M., Liotta L.A., Petricoin E.F. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002, 2:312-320.
18. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
19. Petricoin E.F., Ornstein D.K., Paweletz C.P., Ardekani A., Hackett P.S., Hitt B.A., et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002, 94:1576-1578.
20. Eckel-Passow J.E., Mahoney D.W., Oberg A.L., Zenka R.M., Johnson K.L., Nair K.S., et al. Bi-Linear Regression for O Quantification: Modeling across the elution profile. J Proteomics Bioinform 2010, 3:314-320.
21. Marshall J., Kupchak P., Zhu W., Yantha J., Vrees T., Furesz S., et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003, 2:361-372.
22. Florentinus A.K., Jankowski A., Petrenko V., Bowden P., Marshall J.G. The Fc receptor-cytoskeleton complex from human neutrophils. J Proteomics 2011, 75:450-468.
23. Bowden P., Pendrak V., Zhu P., Marshall J.G. Meta sequence analysis of human blood peptides and their parent proteins. J Proteomics 2010, 73:1163-1175.
24. Tucholska M., Bowden P., Jacks K., Zhu P., Furesz S., Dumbrovsky M., et al. Human serum proteins fractionated by preparative partition chromatography prior to LC-ESI-MS/MS. J Proteome Res 2009, 8:1143-1155.
25. Williams D., Ackloo S., Zhu P., Bowden P., Evans K.R., Addison C.L., et al. Precipitation and selective extraction of human serum endogenous peptides with analysis by quadrupole time-of-flight mass spectrometry reveals posttranslational modifications and low-abundance peptides. Anal Bioanal Chem 2010, 396:1223-1247.
26. Benjamini Y., Hochberg Y. Controlling false discovery rate: a practical approach to multiple testing. J R Stat Soc 1995, 57:289-300.
27. Anderle M., Roy S., Lin H., Becker C., Joho K. Quantifying reproducibility for differential proteomics: noise analysis for protein liquid chromatography-mass spectrometry of human serum. Bioinformatics 2004, 20:3575-3582.
28. Baggerly K.A., Morris J.S., Wang J., Gold D., Xiao L.C., Coombes K.R. A comprehensive approach to the analysis of matrix-assisted laser desorption/ionization-time of flight proteomics spectra from serum samples. Proteomics 2003, 3:1667-1672.
29. Sorace J.M., Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003, 4:24.
30. Baggerly K.A., Morris J.S., Coombes K.R. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004, 20:777-785.
31. Eckel-Passow J.E., Oberg A.L., Therneau T.M., Bergen H.R. An insight into high-resolution mass-spectrometry data. Biostatistics 2009, 10:481-500.
32. Marshall J., Jankowski A., Furesz S., Kireeva I., Barker L., Dombrovsky M., et al. Human serum proteins preseparated by electrophoresis or chromatography followed by tandem mass spectrometry. J Proteome Res 2004, 3:364-382.
33. Tucholska M., Florentinus A., Williams D., Marshall J.G. The endogenous peptides of normal human serum extracted from the acetonitrile-insoluble precipitate using modified aqueous buffer with analysis by LC-ESI-Paul ion trap and Qq-TOF. J Proteomics 2010, 73:1254-1269.
34. Oberg A.L., Mahoney D.W., Eckel-Passow J.E., Malone C.J., Wolfinger R.D., Hill E.G., et al. Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA. J Proteome Res 2008, 7:225-233.
35. Xia J.Q., Sedransk N., Feng X. Variance component analysis of a multi-site study for the reproducibility of multiple reaction monitoring measurements of peptides in human plasma. PLoS One 2011, 6:e14590.
36. Aguilera R., Hatton C.K., Catlin D.H. Detection of epitestosterone doping by isotope ratio mass spectrometry. Clin Chem 2002, 48:629-636.
37. Arneberg R., Rajalahti T., Flikka K., Berven F.S., Kroksveen A.C., Berle M., et al. Pretreatment of mass spectral profiles: application to proteomic data. Anal Chem 2007, 79:7014-7026.
38. Hastings C.A., Norton S.M., Roy S. New algorithms for processing and peak detection in liquid chromatography/mass spectrometry data. Rapid Commun Mass Spectrom 2002, 16:462-467.
39. van Hemert M.J., Steensma H.Y., van Heusden G.P. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 2001, 23:936-946.
40. Powell D.W., Rane M.J., Joughin B.A., Kalmukova R., Hong J.H., Tidor B., et al. Proteomic identification of 14-3-3zeta as a mitogen-activated protein kinase-activated protein kinase 2 substrate: role in dimer formation and ligand binding. Mol Cell Biol 2003, 23:5376-5387.
41. Pozuelo Rubio M., Geraghty K.M., Wong B.H., Wood N.T., Campbell D.G., Morrice N., et al. 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J 2004, 379:395-408.
42. Gao J., Garulacan L.A., Storm S.M., Opiteck G.J., Dubaquie Y., Hefta S.A., et al. Biomarker discovery in biological fluids. Methods 2005, 35:291-302.
43. Sardana G., Marshall J., Diamandis E.P. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin Chem 2007, 53:429-437.
44. Declan Williams P.Z., Bowden Peter, Stacey Catherine, McDonell Mike, Kowalski Paul, Kowalski Jane Marie, et al. Comparison of methods to examine the endogenous peptides of fetal calf serum clinical proteomics. Clin Proteomics 2007, 2:67-89.
45. Zhu P., Bowden P., Pendrak V., Thiele H., Zhang D., Siu M., et al. Comparison of protein expression lists from mass spectrometry of human blood fluids using exact peptide sequences versus BLAST. Clin Proteomics 2007, 2:185-203.
46. Gupta N., Bandeira N., Keich U., Pevzner P.A. Target-decoy approach and false discovery rate: when things may go wrong. J Am Soc Mass Spectrom 2011, 22:1111-1120.
47. Zhang R., Barker L., Pinchev D., Marshall J., Rasamoelisolo M., Smith C., et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004, 4:244-256.
48. Jankowski A., Zhu P., Marshall J.G. Capture of an activated receptor complex from the surface of live cells by affinity receptor chromatography. Anal Biochem 2008, 380:235-248.
49. Kolialexi A., Tsangaris G.T., Papantoniou N., Anagnostopoulos A.K., Vougas K., Bagiokos V., et al. Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma. Prenat Diagn 2008, 28:691-698.
50. Xing G., Zhang J., Chen Y., Zhao Y. Identification of four novel types of in vitro protein modifications. J Proteome Res 2008, 7:4603-4608.
51. Wang K.Y., Chuang S.A., Lin P.C., Huang L.S., Chen S.H., Ouarda S., et al. Multiplexed immunoassay: quantitation and profiling of serum biomarkers using magnetic nanoprobes and MALDI-TOF MS. Anal Chem 2008, 80:6159-6167.
52. Nicol G.R., Han M., Kim J., Birse C.E., Brand E., Nguyen A., et al. Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. Mol Cell Proteomics 2008, 7:1974-1982.
53. Marchi N., Mazzone P., Fazio V., Mekhail T., Masaryk T., Janigro D. ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients. Cancer 2008, 112:1313-1324.
54. Luque-Garcia J.L., Zhou G., Spellman D.S., Sun T.T., Neubert T.A. Analysis of electroblotted proteins by mass spectrometry: protein identification after Western blotting. Mol Cell Proteomics 2008, 7:308-314.
55. Hao Y., Yu Y., Wang L., Yan M., Ji J., Qu Y., et al. IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J Proteome Res 2008, 7:3668-3677.
56. Barba de la Rosa A.P., Lugo-Melchor O.Y., Briones-Cerecero E.P., Chagolla-Lopez A., De Leon-Rodriguez A., Santos L., et al. Analysis of human serum from women affected by cervical lesions. J Exp Ther Oncol 2008, 7:65-72.
57. Morgan P.E., Sturgess A.D., Hennessy A., Davies M.J. Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis. Free Radic Res 2007, 41:1301-1312.
58. Haqqani A.S., Hutchison J.S., Ward R., Stanimirovic D.B. Biomarkers and diagnosis; protein biomarkers in serum of pediatric patients with severe traumatic brain injury identified by ICAT-LC-MS/MS. J Neurotrauma 2007, 24:54-74.
59. Yokoi K., Shih L.C., Kobayashi R., Koomen J., Hawke D., Li D., et al. Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int J Oncol 2005, 27:1361-1369.
60. Malik G., Ward M.D., Gupta S.K., Trosset M.W., Grizzle W.E., Adam B.L., et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005, 11:1073-1085.
61. Zhao X., Okeke N.L., Sharpe O., Batliwalla F.M., Lee A.T., Ho P.P., et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 2008, 10:R94.
62. Reichel C. Identification of zinc-alpha-2-glycoprotein binding to clone AE7A5 antihuman EPO antibody by means of nano-HPLC and high-resolution high-mass accuracy ESI-MS/MS. J Mass Spectrom 2008, 43:916-923.
63. Plavina T., Hincapie M., Wakshull E., Subramanyam M., Hancock W.S. Increased plasma concentrations of cytoskeletal and Ca2+-binding proteins and their peptides in psoriasis patients. Clin Chem 2008, 54:1805-1814.
64. Hammerer-Lercher A., Halfinger B., Sarg B., Mair J., Puschendorf B., Griesmacher A., et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 2008, 54:858-865.
65. Gramolini A.O., Kislinger T., Alikhani-Koopaei R., Fong V., Thompson N.J., Isserlin R., et al. Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Mol Cell Proteomics 2008, 7:519-533.
66. Wilson A.M., Kimura E., Harada R.K., Nair N., Narasimhan B., Meng X.Y., et al. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 2007, 116:1396-1403.
67. Kulasingam V., Smith C.R., Batruch I., Buckler A., Jeffery D.A., Diamandis E.P. "Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap. J Proteome Res 2008, 7:640-647.
68. Yang Z., Harris L.E., Palmer-Toy D.E., Hancock W.S. Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. Clin Chem 2006, 52:1897-1905.
69. Reynolds M.A., Kirchick H.J., Dahlen J.R., Anderberg J.M., McPherson P.H., Nakamura K.K., et al. Early biomarkers of stroke. Clin Chem 2003, 49:1733-1739.
70. Fortin T., Salvador A., Charrier J.P., Lenz C., Lacoux X., Morla A., et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteomics 2009, 8:1006-1015.
71. Qian M., Sleat D.E., Zheng H., Moore D., Lobel P. Proteomics analysis of serum from mutant mice reveals lysosomal proteins selectively transported by each of the two mannose 6-phosphate receptors. Mol Cell Proteomics 2008, 7:58-70.
72. Plavina T., Wakshull E., Hancock W.S., Hincapie M. Combination of abundant protein depletion and multi-lectin affinity chromatography (M-LAC) for plasma protein biomarker discovery. J Proteome Res 2007, 6:662-671.
73. Zenzmaier C., Marksteiner J., Kiefer A., Berger P., Humpel C. Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients. J Neurochem 2009, 110:653-661.
74. Ma Y., Peng J., Liu W., Zhang P., Huang L., Gao B., et al. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteomics 2009, 8:1878-1890.
75. Chelius D., Huhmer A.F., Shieh C.H., Lehmberg E., Traina J.A., Slattery T.K., et al. Analysis of the adenovirus type 5 proteome by liquid chromatography and tandem mass spectrometry methods. J Proteome Res 2002, 1:501-513.
76. Moore R.E., Young M.K., Lee T.D. Qscore: an algorithm for evaluating SEQUEST database search results. J Am Soc Mass Spectrom 2002, 13:378-386.
77. Park S.K., M.K. Random Number Generators: Good Ones Are Hard To Find. Commun ACM 1988, 31:1191-1201.
78. Cargile B.J., Bundy J.L., Stephenson J.L. Potential for false positive identifications from large databases through tandem mass spectrometry. J Proteome Res 2004, 3:1082-1085.
79. Peihong Zhu, PB, Voitek Pendrak, Herbert Thiele, Du Zhang, Michael Siu, Eleftherios P., Diamandis, John Marshall Comparison of protein expression lists from mass spectrometry of human blood fluids using exact peptide sequences versus BLAST. Clin Proteomics 2006, 3-4:185-203.
80. Mann B., Madera M., Sheng Q., Tang H., Mechref Y., Novotny M.V. ProteinQuant Suite: a bundle of automated software tools for label-free quantitative proteomics. Rapid Commun Mass Spectrom 2008, 22:3823-3834.